periplogenin has been researched along with Esophageal Squamous Cell Carcinoma in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, H; Chen, Y; Dong, Z; Gu, T; Hu, Y; Jia, X; Liu, F; Liu, H; Liu, K; Liu, T; Wang, P; Wei, H; Yang, R; Zhao, J | 1 |
1 other study(ies) available for periplogenin and Esophageal Squamous Cell Carcinoma
| Article | Year |
|---|---|
Periplogenin suppresses the growth of esophageal squamous cell carcinoma in vitro and in vivo by targeting STAT3.
Topics: Aged; Aged, 80 and over; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Digitoxigenin; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Humans; Male; Middle Aged; Phosphorylation; Signal Transduction; STAT3 Transcription Factor; Survival Rate; Xenograft Model Antitumor Assays | 2021 |